Auris Medical Holding AG (EARS) Shares Down NaN
Auris Medical Holding AG (NASDAQ:EARS) dropped NaN during trading on Tuesday . The stock traded as low as $0.70 and last traded at $0.00. Approximately 524,700 shares traded hands during mid-day trading, an increase of Infinity from the average daily volume of 0 shares.
EARS has been the subject of several recent research reports. ValuEngine cut Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Roth Capital reissued a “buy” rating and issued a $5.00 price target on shares of Auris Medical Holding AG in a research note on Saturday, July 1st. Finally, Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Auris Medical Holding AG has a consensus rating of “Hold” and a consensus target price of $3.25.
The stock’s market capitalization is $34.93 million. The company’s 50 day moving average is $0.71 and its 200 day moving average is $0.75.
Auris Medical Holding AG (NASDAQ:EARS) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.09. Equities analysts expect that Auris Medical Holding AG will post ($0.63) earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in EARS. Sabby Management LLC acquired a new stake in Auris Medical Holding AG in the 1st quarter valued at approximately $133,000. Perceptive Advisors LLC acquired a new stake in Auris Medical Holding AG in the 1st quarter valued at approximately $368,000. UBS Oconnor LLC acquired a new stake in Auris Medical Holding AG in the 1st quarter valued at approximately $909,000. Finally, Virtu KCG Holdings LLC acquired a new stake in Auris Medical Holding AG in the 2nd quarter valued at approximately $101,000. 28.38% of the stock is currently owned by institutional investors and hedge funds.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.